Can we target KRAS effectively in advanced NSCLC?

07/02/13 • 4 min

1 Listener

Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.

Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.

Previous Episode

undefined - Dr. Geoffrey Oxnard: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?

Dr. Geoffrey Oxnard: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

Next Episode

Dr. Rosalyn Juergens: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?

Dr. Rosalyn Juergens, McMaster University, reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.